Abivax S.A. is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod, is an oral small molecule designed to enhance the expression of microRNA-124 and is currently in late-stage clinical trials for the treatment of ulcerative colitis and Crohn's disease.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
4,570
12,449
4,621
4,583
Gross Profit
4,570
12,449
4,621
4,583
Selling, General & Administrative Expenses
72,864
38,900
28,821
7,492
Research & Development Expenses
177,761
146,532
103,176
48,295
Other Operating Expenses
—
—
—
13,632
Operating Profit
(246,056)
(172,984)
(127,376)
(64,836)
Interest and Investment Income
27,545
13,732
7,511
11,118
Interest Expense
(111,743)
(16,991)
(27,875)
(7,022)
Total Non-Operating Income
(84,198)
(3,259)
(20,364)
4,096
Income Before Provision for Income Taxes
(330,254)
(176,242)
(147,740)
(60,740)
Provision for Income Taxes
(5,848)
—
—
—
Consolidated Net Income
(324,406)
(176,242)
(147,740)
(60,740)
Net Income Attributable to Common Shareholders
(336,102)
(176,242)
(147,740)
(60,740)
Basic EPS
-4.83
-2.80
-3.43
-3.18
Diluted EPS
-4.83
-2.80
-3.43
-3.18
Basic Weighted Average Shares Outstanding
69,527
63,046
43,066
19,092
Diluted Weighted Average Shares Outstanding
69,527
63,046
43,066
19,092
Shares Outstanding
78,536
63,348
62,917
22,301
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
516,685
144,221
251,942
26,950
Total Cash and Cash Equivalents
516,685
144,221
251,942
26,950
Other Receivables
21,415
7,554
9,186
—
Total Trade Receivables
21,415
7,554
9,186
—
Other Current Assets
13,144
18,896
24,845
9,231
Total Current Assets
551,244
170,671
285,972
36,181
Net Property, Plant & Equipment
2,090
2,666
878
1,592
Net Intangible Assets
6,605
6,606
6,604
6,607
Goodwill
18,419
18,419
18,419
18,419
Other Long-Term Assets
5,983
6,867
15,190
12,745
Total Assets
584,341
205,228
327,062
75,544
Accounts Payable
37,552
43,824
47,221
15,475
Accrued Expenses
7,137
4,709
6,073
2,300
Current Portion of Long-Term Debt
1,302
43,769
31,260
30,034
Unearned Revenue
—
—
52
133
Other Current Liabilities
17,030
1,698
6,088
3,521
Total Current Liabilities
63,021
93,999
90,695
51,464
Long-Term Debt
554
52,426
24,206
9,127
Other Long-Term Liabilities
65,561
18,218
16,150
7,765
Total Long-Term Liabilities
66,114
70,645
40,356
16,891
Total Liabilities
129,135
164,644
131,051
68,355
Common Stock
785
633
629
223
Additional Paid-in Capital
1,190,593
478,905
478,218
150,476
Accumulated Other Comprehensive Income
2,309
(75)
112
—
Retained Earnings
(738,482)
(438,879)
(282,949)
(143,510)
Total Common Shareholders' Equity
455,205
40,584
196,010
7,189
Total Shareholders' Equity
455,205
40,584
196,010
7,189
Total Liabilities and Shareholders' Equity
584,341
205,228
327,062
75,544
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(336,102)
(176,242)
(147,740)
(60,740)
Depreciation & Amortization
1,072
1,100
707
485
Share-Based Compensation Expense
35,397
20,224
8,179
(1,164)
Other Adjustments
134,851
(578)
20,458
9,488
Changes in Accounts Payable
(6,210)
(3,444)
31,757
(2,388)
Changes in Accrued Expenses
2,110
(1,487)
3,821
100
Changes in Other Operating Activities
7,752
6,354
(14,312)
286
Cash from Operating Activities
(161,129)
(154,072)
(97,130)
(53,936)
Capital Expenditure
(142)
(640)
(265)
(288)
Purchases of Intangible Assets
—
(3)
—
(35)
Payments for Business Acquisitions
—
—
—
(2,913)
Other Investing Activities
(8,051)
16,406
(7,830)
(8,885)
Cash from Investing Activities
(8,193)
15,762
(8,095)
(12,026)
Issuance of Long-Term Debt
—
47,944
55,841
—
Repayments of Long-Term Debt
(58,622)
(12,708)
(40,183)
—
Net Issuance / (Repayments) of Long-Term Debt
(58,622)
35,236
15,658
—
Issuance of Common Shares
613,030
880
325,276
—
Net Issuance / (Repurchases) of Common Shares
613,030
880
325,276
—
Other Financing Activities
(7,101)
(7,909)
(5,645)
—
Cash from Financing Activities
547,307
28,207
335,290
—
Effect of Exchange Rate Changes on Cash and Cash Equivalents
(10,251)
2,382
(5,072)
—
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash